PMID- 15068318
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20190906
IS  - 0284-186X (Print)
IS  - 0284-186X (Linking)
VI  - 43
IP  - 1
DP  - 2004
TI  - Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer 
      investigated by new FISH probes.
PG  - 35-42
AB  - New strategies for improving treatment of patients with breast carcinoma have 
      focused on the HER2 oncoprotein with regard to response to traditional therapy 
      regimes and the effect of a new drug specifically directed against the protein. 
      Furthermore, the status of the topoisomerase IIalpha (TOP2A) gene has been 
      suggested as a predictive marker of anthracycline treatment. In this study of 120 
      tumours, immunohistochemically detected HER2 overexpression with HercepTest has 
      been compared to the HER2 gene amplification investigated with a new HER2 probe 
      for fluorescence in situ hybridization (FISH). In addition, the HercepTest was 
      evaluated as a screening tool for choosing cases for FISH investigation of TOP2A 
      gene aberrations. The HercepTest score 3+ identified HER2 gene amplification in 
      27 of 30 amplified tumours (sensitivity of 0.90) with a false-negative rate of 
      0.10 and a false-positive rate of 0.06. TOP2A gene amplification or deletion was 
      found in 20 cases. Sixteen (80%) of these carcinomas were in the HercepTest 3+ 
      group, but four tumours had alterations in the TOP2A gene with normal HER2 
      status. Traditionally, in the FISH technique the result has been based on 
      counting 60 cells. However, we found that a much less time-consuming method of 
      counting 60 signals gave equally good results.
FAU - Olsen, Karen E
AU  - Olsen KE
AD  - Department of Pathology, Odense University Hospital, Denmark. 
      karen.ege.olsen@ouh.fyns-amt.dk
FAU - Knudsen, Helle
AU  - Knudsen H
FAU - Rasmussen, Birgitte B
AU  - Rasmussen BB
FAU - Balslev, Eva
AU  - Balslev E
FAU - Knoop, Ann
AU  - Knoop A
FAU - Ejlertsen, Bent
AU  - Ejlertsen B
FAU - Nielsen, Kirsten V
AU  - Nielsen KV
FAU - Schonau, Andreas
AU  - Schonau A
FAU - Overgaard, Jens
AU  - Overgaard J
CN  - Danish Breast Cancer Co-operative Group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biopsy, Needle
MH  - Breast Neoplasms/*genetics/pathology
MH  - DNA Topoisomerases, Type II/*genetics
MH  - Female
MH  - Gene Amplification
MH  - Gene Deletion
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2/*genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Sensitivity and Specificity
EDAT- 2004/04/08 05:00
MHDA- 2004/04/24 05:00
CRDT- 2004/04/08 05:00
PHST- 2004/04/08 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2004/04/08 05:00 [entrez]
AID - 10.1080/02841860310019007 [doi]
PST - ppublish
SO  - Acta Oncol. 2004;43(1):35-42. doi: 10.1080/02841860310019007.